Patents Assigned to TIGEN PHARMA SA
  • Publication number: 20260183397
    Abstract: The present invention relates to a method for expansion of a population of lymphocytes in a controlled single culture vessel, the method comprising a step of (a) culturing a tissue or blood sample from a subject, which sample is known or suspected to contain lymphocytes; or (b) culturing lymphocytes, which lymphocytes are isolated from a tissue or blood sample from a subject; wherein the lymphocytes are expanded in a culture medium in which at least one of the following parameters is monitored and adjusted to a predefined value or range: pH, dissolved oxygen (DO) concentration, glucose concentration, lactate concentration and/or temperature; and wherein the method comprises a step of adjusting the culture volume to the expansion rate of the lymphocytes.
    Type: Application
    Filed: November 2, 2023
    Publication date: July 2, 2026
    Applicants: TIGEN PHARMA SA, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)
    Inventors: Therese Choquette, George Coukos, Alexandre Harari, Simone Steiner
  • Publication number: 20240287454
    Abstract: The present invention relates to a population of lymphocytes comprising at least 90% CD3+ T cells and less than 5% B cells, wherein at least 70% of said T cell portion are viable, at least 20% are CD27/CD28 double positive and less than 10% are triple positive for CD45RA, CD57 and KLRG1 and a method for expansion of a population of lymphocytes specific for one or more antigens comprising a single culture phase.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 29, 2024
    Applicants: TIGEN PHARMA SA, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)
    Inventors: George Coukos, Alexandre Harari, Simone Steiner, Florence Salmon